NCI’s use of Cancer Dialogue for biospecimen network blueprint raises legal, procedural questions.
Plan posted for “public comment” on Dialogue’s Web site; who will respond, Dialogue or NCI? Cost estimate of network significantly reduced.
Also Stillman named director, Cold Spring Harbor, Watson is chancellor.
Pollin Prize honors four pioneers in treatment of childhood leukemia.
December Business & Regulatory Report included in this issue.
The Cancer Letter takes two-week break; next issue Jan. 2.
Trending Stories
- Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit - NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - Bhattacharya cancels NIH all-hands meeting
- In the Headlines: “There’s no one to stand up for NCI right now.”
- An opportunity for Trump: Position U.S. cancer science to lead the world
- Cyber-iconoclast Vinay Prasad named head of FDA’s CBER
An oncologist, Prasad has criticized accelerated approval, next-gen sequencing, and targeted therapies